Free Trial
→ Nobody Understands Why Trump Is Invading Iran (here’s the answer) (From Banyan Hill Publishing) (Ad)tc pixel Free GLUE Stock Alerts

Monte Rosa Therapeutics (GLUE) Competitors

Monte Rosa Therapeutics logo
$19.35 -0.22 (-1.12%)
Closing price 04:00 PM Eastern
Extended Trading
$19.34 -0.01 (-0.05%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

GLUE vs. MIRM, CNTA, CGON, SYRE, and GRFS

Should you be buying Monte Rosa Therapeutics stock or one of its competitors? The main competitors of Monte Rosa Therapeutics include Mirum Pharmaceuticals (MIRM), Centessa Pharmaceuticals (CNTA), CG Oncology (CGON), Spyre Therapeutics (SYRE), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry.

How does Monte Rosa Therapeutics compare to Mirum Pharmaceuticals?

Monte Rosa Therapeutics (NASDAQ:GLUE) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

In the previous week, Mirum Pharmaceuticals had 22 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 25 mentions for Mirum Pharmaceuticals and 3 mentions for Monte Rosa Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 0.98 beat Mirum Pharmaceuticals' score of 0.45 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Monte Rosa Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Mirum Pharmaceuticals
10 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Monte Rosa Therapeutics has a beta of 1.62, indicating that its share price is 62% more volatile than the S&P 500. Comparatively, Mirum Pharmaceuticals has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500.

80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. 6.5% of Monte Rosa Therapeutics shares are owned by company insiders. Comparatively, 22.9% of Mirum Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Monte Rosa Therapeutics presently has a consensus price target of $32.80, indicating a potential upside of 69.51%. Mirum Pharmaceuticals has a consensus price target of $125.25, indicating a potential upside of 18.37%. Given Monte Rosa Therapeutics' higher probable upside, analysts clearly believe Monte Rosa Therapeutics is more favorable than Mirum Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Monte Rosa Therapeutics
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63
Mirum Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.93

Mirum Pharmaceuticals has a net margin of -4.48% compared to Monte Rosa Therapeutics' net margin of -31.23%. Mirum Pharmaceuticals' return on equity of -8.53% beat Monte Rosa Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Monte Rosa Therapeutics-31.23% -15.12% -9.30%
Mirum Pharmaceuticals -4.48%-8.53%-3.07%

Mirum Pharmaceuticals has higher revenue and earnings than Monte Rosa Therapeutics. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Monte Rosa Therapeutics$123.67M13.20-$38.63M-$0.46N/A
Mirum Pharmaceuticals$521.31M12.38-$23.36M-$0.48N/A

Summary

Mirum Pharmaceuticals beats Monte Rosa Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Monte Rosa Therapeutics compare to Centessa Pharmaceuticals?

Centessa Pharmaceuticals (NASDAQ:CNTA) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations.

Centessa Pharmaceuticals has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -31.23%. Monte Rosa Therapeutics' return on equity of -15.12% beat Centessa Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Centessa PharmaceuticalsN/A -50.66% -36.65%
Monte Rosa Therapeutics -31.23%-15.12%-9.30%

Monte Rosa Therapeutics has higher revenue and earnings than Centessa Pharmaceuticals. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Centessa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Centessa Pharmaceuticals$15M394.66-$197.53M-$1.47N/A
Monte Rosa Therapeutics$123.67M13.20-$38.63M-$0.46N/A

Centessa Pharmaceuticals presently has a consensus price target of $40.70, indicating a potential upside of 2.60%. Monte Rosa Therapeutics has a consensus price target of $32.80, indicating a potential upside of 69.51%. Given Monte Rosa Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Monte Rosa Therapeutics is more favorable than Centessa Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Centessa Pharmaceuticals
1 Sell rating(s)
9 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.21
Monte Rosa Therapeutics
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63

82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. 7.1% of Centessa Pharmaceuticals shares are owned by company insiders. Comparatively, 6.5% of Monte Rosa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Centessa Pharmaceuticals and Centessa Pharmaceuticals both had 3 articles in the media. Monte Rosa Therapeutics' average media sentiment score of 0.98 beat Centessa Pharmaceuticals' score of 0.10 indicating that Monte Rosa Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Centessa Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Monte Rosa Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Centessa Pharmaceuticals has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500. Comparatively, Monte Rosa Therapeutics has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500.

Summary

Monte Rosa Therapeutics beats Centessa Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does Monte Rosa Therapeutics compare to CG Oncology?

Monte Rosa Therapeutics (NASDAQ:GLUE) and CG Oncology (NASDAQ:CGON) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

Monte Rosa Therapeutics currently has a consensus price target of $32.80, suggesting a potential upside of 69.51%. CG Oncology has a consensus price target of $79.55, suggesting a potential upside of 18.41%. Given Monte Rosa Therapeutics' higher possible upside, analysts plainly believe Monte Rosa Therapeutics is more favorable than CG Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Monte Rosa Therapeutics
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63
CG Oncology
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.77

80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 26.6% of CG Oncology shares are held by institutional investors. 6.5% of Monte Rosa Therapeutics shares are held by insiders. Comparatively, 4.8% of CG Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, CG Oncology had 3 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 6 mentions for CG Oncology and 3 mentions for Monte Rosa Therapeutics. CG Oncology's average media sentiment score of 1.31 beat Monte Rosa Therapeutics' score of 0.98 indicating that CG Oncology is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Monte Rosa Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
CG Oncology
4 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Monte Rosa Therapeutics has higher revenue and earnings than CG Oncology. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Monte Rosa Therapeutics$123.67M13.20-$38.63M-$0.46N/A
CG Oncology$4.04M1,463.49-$160.99M-$2.07N/A

Monte Rosa Therapeutics has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500. Comparatively, CG Oncology has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500.

CG Oncology has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -31.23%. Monte Rosa Therapeutics' return on equity of -15.12% beat CG Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Monte Rosa Therapeutics-31.23% -15.12% -9.30%
CG Oncology N/A -22.87%-21.82%

Summary

Monte Rosa Therapeutics beats CG Oncology on 9 of the 15 factors compared between the two stocks.

How does Monte Rosa Therapeutics compare to Spyre Therapeutics?

Monte Rosa Therapeutics (NASDAQ:GLUE) and Spyre Therapeutics (NASDAQ:SYRE) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

Spyre Therapeutics has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -31.23%. Monte Rosa Therapeutics' return on equity of -15.12% beat Spyre Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Monte Rosa Therapeutics-31.23% -15.12% -9.30%
Spyre Therapeutics N/A -41.79%-25.97%

Monte Rosa Therapeutics currently has a consensus price target of $32.80, suggesting a potential upside of 69.51%. Spyre Therapeutics has a consensus price target of $85.08, suggesting a potential upside of 19.82%. Given Monte Rosa Therapeutics' higher possible upside, analysts plainly believe Monte Rosa Therapeutics is more favorable than Spyre Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Monte Rosa Therapeutics
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63
Spyre Therapeutics
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
2 Strong Buy rating(s)
3.00

In the previous week, Spyre Therapeutics had 17 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 20 mentions for Spyre Therapeutics and 3 mentions for Monte Rosa Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 0.98 beat Spyre Therapeutics' score of 0.43 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Monte Rosa Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Spyre Therapeutics
7 Very Positive mention(s)
5 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Monte Rosa Therapeutics has higher revenue and earnings than Spyre Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Spyre Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Monte Rosa Therapeutics$123.67M13.20-$38.63M-$0.46N/A
Spyre Therapeutics$890K6,285.58-$155.20M-$2.08N/A

80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are held by institutional investors. 6.5% of Monte Rosa Therapeutics shares are held by insiders. Comparatively, 15.7% of Spyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Monte Rosa Therapeutics has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500. Comparatively, Spyre Therapeutics has a beta of 3.12, meaning that its stock price is 212% more volatile than the S&P 500.

Summary

Spyre Therapeutics beats Monte Rosa Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Monte Rosa Therapeutics compare to Grifols?

Monte Rosa Therapeutics (NASDAQ:GLUE) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Grifols has a net margin of 5.34% compared to Monte Rosa Therapeutics' net margin of -31.23%. Grifols' return on equity of 6.23% beat Monte Rosa Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Monte Rosa Therapeutics-31.23% -15.12% -9.30%
Grifols 5.34%6.23%2.40%

Grifols has higher revenue and earnings than Monte Rosa Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Monte Rosa Therapeutics$123.67M13.20-$38.63M-$0.46N/A
Grifols$8.51B0.66$454.82M$0.1943.53

In the previous week, Monte Rosa Therapeutics had 2 more articles in the media than Grifols. MarketBeat recorded 3 mentions for Monte Rosa Therapeutics and 1 mentions for Grifols. Monte Rosa Therapeutics' average media sentiment score of 0.98 beat Grifols' score of 0.05 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Monte Rosa Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Grifols
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

80.0% of Monte Rosa Therapeutics shares are held by institutional investors. 6.5% of Monte Rosa Therapeutics shares are held by insiders. Comparatively, 0.2% of Grifols shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Monte Rosa Therapeutics has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500. Comparatively, Grifols has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500.

Monte Rosa Therapeutics currently has a consensus price target of $32.80, suggesting a potential upside of 69.51%. Grifols has a consensus price target of $10.00, suggesting a potential upside of 20.92%. Given Monte Rosa Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Monte Rosa Therapeutics is more favorable than Grifols.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Monte Rosa Therapeutics
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63
Grifols
1 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.75

Summary

Monte Rosa Therapeutics beats Grifols on 9 of the 15 factors compared between the two stocks.

Get Monte Rosa Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GLUE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GLUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GLUE vs. The Competition

Export
MetricMonte Rosa TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.65B$3.39B$6.24B$11.86B
Dividend YieldN/A2.20%2.73%5.21%
P/E RatioN/A38.8529.0428.48
Price / Sales13.20157.28477.1060.43
Price / CashN/A57.8827.6236.52
Price / Book5.417.039.676.67
Net Income-$38.63M$23.62M$3.55B$332.64M
7 Day Performance1.79%3.67%1.70%2.01%
1 Month Performance13.22%7.17%5.62%9.19%
1 Year Performance317.93%67.04%34.42%39.59%

Monte Rosa Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GLUE
Monte Rosa Therapeutics
2.2202 of 5 stars		$19.35
-1.1%		$32.80
+69.5%		N/A$1.65B$123.67MN/A90
MIRM
Mirum Pharmaceuticals
2.2543 of 5 stars		$96.87
-0.5%		$121.75
+25.7%		N/A$5.91B$521.31MN/A140
CNTA
Centessa Pharmaceuticals
1.7782 of 5 stars		$39.48
+0.2%		$40.70
+3.1%		N/A$5.89B$15MN/A200
CGON
CG Oncology
3.3852 of 5 stars		$66.40
-0.5%		$79.55
+19.8%		N/A$5.84B$4.04MN/A61
SYRE
Spyre Therapeutics
2.704 of 5 stars		$73.45
-1.3%		$85.08
+15.8%		N/A$5.79B$890KN/A73

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:GLUE) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel
URGENT: $2 Gold Stock With Major Discovery
A $2 gold stock is said to quietly control what may be the largest gold deposit in the world - worth nearly $1...
Paradigm Press | Sponsoredtc pixel